Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/129803
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Safety of maternal pertussis vaccination on pregnancy and birth outcomes: a prospective cohort study |
Author: | Mohammed, H. Roberts, C.T. Grzeskowiak, L.E. Giles, L.C. Verburg, P. Dekker, G. Marshall, H.S. |
Citation: | Vaccine, 2021; 39(2):324-331 |
Publisher: | Elsevier |
Issue Date: | 2021 |
ISSN: | 0264-410X 1873-2518 |
Statement of Responsibility: | Hassen Mohammed, Claire T Roberts, Luke E Grzeskowiak, Lynne C Giles, Petra E Verburg, Gustaaf Dekker, Helen S Marshall |
Abstract: | OBJECTIVE: To evaluate the safety of maternal pertussis vaccination on pregnancy and birth outcomes. METHODS: The study population comprised 1272 healthy nulliparous pregnant women who participated in Screening Tests to identify poor Outcomes in Pregnancy (STOP) study at two obstetric hospitals in South Australia between 2015 and 2018. Participants were followed prospectively, with vaccination (confirmed by medical records), extensive amounts of pregnancy and birth outcome data collected by research midwives. Adjusted relative risks (aRRs) and hazard ratios (aHRs) were estimated accounting for time-varying vaccine exposure and the temporal nature of each outcome. RESULTS: Of the 1272 women included in this study, 80.1% (n = 1019) received maternal pertussis vaccination. Vaccinated women had an average 0.22 weeks (95% CI 0.001, 0.44) longer gestation at delivery compared to unvaccinated women. Maternal pertussis vaccination was not associated with chorioamnionitis (aRR 0.71, 95% CI 0.27,1.82), gestational hypertension (aHR 1.24, 95% CI, 0.66, 2.30), preeclampsia (aHR 0.75, 95% CI 0.47, 1.18) nor preterm birth (aHR 0.99, 95% CI 0.47, 2.07). Neither risk of low birth weight (aHR 0.72, 95% CI 0.41, 1.27) nor small for gestational age infants (aHR 0.67,95% CI 0.29, 1.55) were increased following maternal pertussis vaccination. No associations between pertussis vaccination during pregnancy and adverse birth outcomes including admission to the neonatal care unit, low Apgar scores, and mechanical ventilation were observed. Results were not materially changed after adjustment for maternal influenza vaccination. CONCLUSION: Our study provides reassuring evidence of the safety of maternal pertussis vaccination with no increased risk of adverse pregnancy and birth outcomes. These findings support recommendations for pertussis vaccination during pregnancy to prevent morbidity and mortality associated with early-infant pertussis disease. |
Keywords: | Infants Maternal vaccination Pertussis Pregnant women Safety Tdap |
Rights: | © 2020 Elsevier Ltd. All rights reserved. |
DOI: | 10.1016/j.vaccine.2020.11.052 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1174971 |
Published version: | http://dx.doi.org/10.1016/j.vaccine.2020.11.052 |
Appears in Collections: | Aurora harvest 8 Obstetrics and Gynaecology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.